Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

[get_header_links]

IVD Market Update

LabCorp, Sysmex Will Collaborate To Develop Liquid Biopsy Tests

NeoGenomics announces 12 assays with liquid biopsy technology to detect tumors, monitor patients’ response

By Robert Michel
[display_issue_on_post]

[get_prev_post_links]

[get_next_post_links]

ANOTHER SIGN OF HEALTHCARE’S TRANSFORMATION came on June 1 when Sysmex Corporation of Kobe, Japan, and Laboratory Corporation of America in Burlington, North Carolina, announced a unique collaboration to develop blood-based molecular diagnostic tests for cancer.
The collaboration calls for Sysmex, a major in vitro diagnostics (IVD) manufacturer with expertise in hematology testing, to work with LabCorp. Efforts will center around two assays developed at Sysmex Inostics, called OncoBEAM and Plasma-Sequencing.

To access this post, you must purchase The Dark Report.

Tags: biopsies, biopsy, biopsy test, clinical trials, Diagnostic tests, generation sequencing, genomics, hematology, lab test, lab tests, molecular diagnostic, molecular diagnostic test, molecular diagnostic tests, tests for cancer

[get_prev_post_links]

[get_next_post_links]

Comments

[get_issue_sidebar]

Need A Group Membership? Company Discounts are Available!

;

LabCorp, Sysmex Will Collaborate To Develop Liquid Biopsy Tests

NeoGenomics announces 12 assays with liquid biopsy technology to detect tumors, monitor patients’ response

Comments

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

[get_read_articles]